Novel antitumor agents are currently being evaluated in clinical trials for use in various gynecological cancers.
Gynecologic Cancer
The search for gynecologic cancer biomarkers that are prognostic or predictive of patient responses to treatment is an active and fruitful area of investigation.
Screening techniques for use in the general population have long been available for cervical cancer and are being actively developed for ovarian cancers.
In the past decade, there has been a rapid increase in the understanding of how various cancers develop and progress.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
